| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10637-014-0078-5 |
| P698 | PubMed publication ID | 24619298 |
| P50 | author | Pingfu Fu | Q63677685 |
| P2093 | author name string | John J Wright | |
| Robert M Wenham | |||
| Afshin Dowlati | |||
| Nancy Fusco | |||
| Vivian E von Gruenigen | |||
| Steven Waggoner | |||
| Heidi Frasure | |||
| Susan Eaton | |||
| Anita Schwandt | |||
| P2860 | cites work | Mutations of the BRAF gene in human cancer | Q27860760 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial | Q30429122 | ||
| Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. | Q33397386 | ||
| Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience | Q33399986 | ||
| Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity | Q33658626 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer | Q36623268 | ||
| Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial | Q36680034 | ||
| Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib | Q36781452 | ||
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
| Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium | Q42905241 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. | Q45930106 | ||
| Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. | Q46029883 | ||
| Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene | Q46200338 | ||
| Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
| Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib | Q46535532 | ||
| Point mutation of the ras oncogene in human ovarian cancer | Q70477544 | ||
| Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma | Q74463809 | ||
| Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1 | Q82567338 | ||
| Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study | Q84491268 | ||
| P433 | issue | 4 | |
| P921 | main subject | uterine tube | Q1233836 |
| fallopian tube cancer | Q4818922 | ||
| fallopian tube carcinoma | Q18554948 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 729-738 | |
| P577 | publication date | 2014-03-12 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer | |
| P478 | volume | 32 |
| Q26779120 | Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer |
| Q38813996 | Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature. |
| Q36270115 | Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review |
| Q47096976 | Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q50345037 | The rise of genomic profiling in ovarian cancer |
| Q55385227 | Tumor angiogenesis and anti-angiogenic gene therapy for cancer. |
Search more.